SARS-CoV-2 cytopathic effect (CPE)

SARS-CoV-2 cytopathic effect (CPE) refers to the observable morphological and structural changes in host cells resulting from infection by the Severe Acute Respiratory Syndrome Coronavirus 2 (StatPearls, 2023). These changes typically include cell rounding, detachment, increased cytoplasmic granularity, and the formation of multinucleated giant cells known as syncytia, which occur when the viral Spike protein facilitates the fusion of infected cells with neighboring healthy cells (Nature, 2020). CPE is the cumulative result of the viral life cycle, including the hijacking of host protein synthesis, the accumulation of viral components, and the eventual induction of programmed cell death pathways such as apoptosis or pyroptosis (PubMed, 2021). In drug discovery and virology research, CPE serves as a critical phenotypic endpoint for high-throughput screening to identify antiviral compounds or neutralizing antibodies that can protect host cells from viral damage (NIH, 2020). While CPE is a physiological outcome of infection rather than a discrete molecular target like a receptor or enzyme, it remains the gold-standard metric for evaluating the efficacy of therapeutics in preventing viral-induced cellular destruction. Drugs such as Remdesivir and Nirmatrelvir reduce CPE by inhibiting viral replication, thereby preserving the integrity and viability of the host cell population (NEJM, 2020).

Other names

Viral cytopathic effectSARS-CoV-2 induced cell deathCPE-mediated cell lysisCytopathogenic effect

Antiviral agents do not target CPE directly; instead, they inhibit viral entry (neutralizing antibodies) or viral replication (protease or polymerase inhibitors), thereby preventing the downstream cellular damage and morphological changes that constitute the cytopathic effect.